Open access
Jul 2026
Cordycepin inhibits pancreatic cancer progression and enhances gemcitabine sensitivity by targeting the CDK2/E2F2 axis to modulate TNNI2 expression.
Cordycepin exerts antitumor activity in pancreatic cancer by targeting the CDK2/E2F2 axis to suppress malignant progression and by concurrently chemosensitizing cells to gemcitabine, thus holding promise as a therapeutic agent.
Ru He, Yan Du, Wenkai Jiang et al.
· Biochemical Pharmacology · 0 citations